Market evolution: Sulphonamides (CN 293590) — 2015–2025

Introduction

This report examines the evolution of European Union trade in sulphonamides under customs code 293590, covering the period from 2017 to 2025 (the available data window). Sulphonamides are a broad class of organic chemicals widely used as intermediates in pharmaceuticals (especially antibiotics) and agrochemicals. The product code 293590 is a residual heading that excludes perfluorooctane sulphonamides (classified separately under codes 293510–293540) and captures a diverse basket of sulphonamide compounds, including the herbicide metosulam and the general-purpose heading 29359090 which accounts for the overwhelming share of trade.

Over the analysed period, the EU's position in the global sulphonamides market underwent a dramatic structural transformation: the Union shifted from being a modest net exporter to a heavily import-dependent economy, with its trade balance swinging by more than €2.5 billion. Several intertwined dynamics drove this shift — collapsing export unit values, surging imports from Switzerland, concentration of supply sources, and declining domestic production volumes — each of which is explored in the sections that follow.

1. From Net Exporter to Net Importer: A Structural Reversal of the EU Trade Balance

The most striking feature of the 2017–2025 period is the EU's transition from a positive to a deeply negative trade balance in sulphonamides. This section documents the scale and timing of this reversal.

1.1 The trade balance swung from surplus to a €1.9 billion deficit

In 2017, the EU exported sulphonamides worth €2.45 billion while importing €1.74 billion, yielding a trade surplus of approximately €715 million. By 2025, exports had contracted to €1.61 billion while imports had ballooned to €3.48 billion, producing a deficit of roughly €1.87 billion. This represents a swing of more than €2.5 billion over the period. (General overview)

1.2 Export volumes held broadly steady while export values collapsed

Despite the sharp decline in export value (−34.3%), the quantity exported barely changed: it moved from 3,822 tonnes in 2017 to 3,912 tonnes in 2025, a modest increase of 2.4%. This decoupling of volume and value points squarely to a dramatic fall in export unit prices, discussed further below. The EU's export base in sulphonamides thus did not erode in terms of physical shipments — it eroded in terms of revenue per unit sold. (General overview)

1.3 Import volumes and values both surged, with prices amplifying the effect

On the import side, quantities rose from 11,716 tonnes to 15,089 tonnes (+28.8%), while import values more than doubled from €1.74 billion to €3.48 billion (+100.6%). The import unit price therefore climbed from approximately €148,000 per tonne to €231,000 per tonne (+55.8%). Unlike exports, where falling prices depressed value despite stable volumes, import growth was magnified by rising unit prices — suggesting that the EU was increasingly sourcing higher-value or scarcer sulphonamide products, or that global pricing conditions shifted to the disadvantage of European buyers. (General overview)

2. Partner Dynamics and Supply Concentration: Switzerland's Rise and the Shifting Geography of Trade

The geographic structure of EU sulphonamides trade changed markedly during the period, with one partner — Switzerland — emerging as a dominant import source and import concentration rising sharply.

2.1 Switzerland became the EU's dominant import partner, accounting for over half of import value

Switzerland's role in EU sulphonamides imports grew explosively: from €224 million in 2017 to €1.87 billion in 2025, an increase of 737.6%. By 2025, Switzerland alone accounted for more than half of total EU import value in this product. This is a remarkable concentration, especially given that Switzerland is not typically associated with bulk chemical production. It likely reflects pharmaceutical-grade sulphonamide intermediates or active ingredient imports routed through Swiss-based trading or manufacturing entities (several major pharmaceutical companies maintain significant Swiss operations). (Top partners by value)

2.2 Import concentration (HHI) nearly tripled, signalling growing supply risk

The Herfindahl-Hirschman Index (HHI) for EU imports by value rose from 1,850 in 2017 to 5,222 in 2025 — an increase of 182.3%. An HHI above 2,500 is generally considered to indicate a highly concentrated market. The surge was driven almost entirely by Switzerland's growing share. By contrast, the HHI for imports by volume increased only modestly (from 2,369 to 2,468), suggesting that while the physical quantities were somewhat more diversified, the high-value segment of imports became highly concentrated in Swiss-origin shipments. (Concentration HHI)

2.3 Export concentration declined as destination markets diversified

On the export side, the picture is almost the reverse. The HHI for EU exports by value fell from 6,299 in 2017 to 4,086 in 2025 (−35.1%), indicating a moderate reduction in destination concentration. The United States remained the single largest export market but its share contracted: exports to the US fell from €1.93 billion to €1.00 billion (−48.1%). Meanwhile, several smaller markets grew — notably Russia (+80.3%), Switzerland (+359.0%), and India (+103.8%) — partially compensating for the US decline. (Top partners by value)

2.4 Ireland's export dominance eroded domestically while Germany and other Member States grew

Among EU Member States, Ireland was the dominant exporter throughout the period, reflecting its large pharmaceutical manufacturing base. However, Irish exports fell from €1.96 billion to €800 million (−59.1%). German exports, by contrast, grew from €67 million to €237 million (+253.0%), and several other Member States (Spain, Slovenia, Italy) also saw meaningful growth. This suggests a gradual redistribution of EU sulphonamide export capacity away from Ireland and toward continental producers. (Top reporters by value)

3. Price Compression, Production Trends, and Sector Specialisation

The third major dynamic is the sharp divergence between export and import unit prices, combined with evolving domestic production patterns and a highly specialised production landscape within the EU.

3.1 Export unit prices fell by over a third, while import prices rose by more than half

The EU export unit price for sulphonamides dropped from approximately €641,000 per tonne in 2017 to €411,000 per tonne in 2025, a decline of 35.9%. The peak was reached in 2019 at roughly €1,096,000 per tonne, after which prices declined steeply. Meanwhile, import unit prices rose from €148,000 to €231,000 per tonne (+55.8%). This divergence means that the EU was exporting relatively expensive, high-specification products (likely pharmaceutical intermediates or finished active ingredients) while increasingly importing lower-priced bulk sulphonamides. The collapse in export prices may reflect increased global competition, particularly from Asian producers, or a shift in the product mix toward lower-value items. (General overview)

3.2 Domestic production volumes declined while values increased, suggesting a shift toward higher-value output

EU production of sulphonamides (under the corresponding PRODCOM code 21.10.32.00) fell in quantity terms from 8.05 million kg in 2017 to 6.73 million kg in 2025 (−16.3%), while production value rose from €372 million to €528 million (+42.0%). This implies a significant increase in the unit value of domestic output, consistent with the hypothesis that EU producers have moved toward higher-value, specialised sulphonamide products while ceding lower-value commodity segments to imports. (Production volumes)

3.3 Ireland and Belgium are the most specialised EU producers, but the sector's overall footprint is narrow

The Revealed Symmetric Comparative Advantage (RSCA) index for 2025 shows Ireland as the most specialised EU Member State in sulphonamide production (RSCA of 0.917, with an RCA of 23.1), followed by Cyprus (0.584) and Belgium (0.280). Ireland alone accounted for roughly 48% of EU production value in this product. The highly concentrated nature of production — with a handful of Member States dominating — underlines the strategic vulnerability of the EU's sulphonamide supply chain, particularly for pharmaceutical applications. Most other Member States show negative or near-zero specialisation, indicating they are net importers of these products. (Most specialised reporters)

3.4 The dominant product sub-segment is the general sulphonamides heading (29359090)

At the six-digit level, code 29359090 (general sulphonamides excluding perfluorooctane sulphonamides, metosulam, and the hexadecylsulphonylamino derivative) accounts for virtually all trade volume and value. The specialised sub-segment 29359030 (metosulam and related compounds) is negligible in comparison — its import quantities ranged from near-zero to at most 13 tonnes per year, with erratic value patterns. All major dynamics described above are therefore driven by the general sulphonamides heading 29359090. (Product compare)

Conclusion

The EU sulphonamides market (CN 293590) underwent a profound structural transformation between 2017 and 2025. The Union shifted from a net exporter with a €715 million surplus to a net importer with a €1.87 billion deficit, driven by a combination of surging import values (particularly from Switzerland, which grew its share by 738%) and collapsing export unit prices (down 36%). Import concentration rose sharply, with the HHI nearly tripling to over 5,200, while export concentration moderately declined as destinations diversified away from the United States.

Domestic production volumes contracted by 16%, though production values rose by 42%, indicating a shift toward higher-value, specialised output — a niche in which Ireland remains the dominant EU player. However, the narrow production base and heavy reliance on Swiss-origin imports expose the EU to significant supply-chain risk in a product class that is critical to the pharmaceutical and agrochemical sectors.

These dynamics carry important policy implications. The combination of rising import dependence, growing supply concentration, and declining export competitiveness suggests that the EU's strategic autonomy in sulphonamides has weakened materially over the period. Stakeholders — from policymakers to industry planners — should monitor whether the current trajectory continues or whether diversification efforts and domestic capacity investments can rebalance the equation in the years ahead.